GlassScriptPhysician profile
James M Francis
NPI 1508878349
$2,913.41
in general payments reported to CMS, 2019-2025
26 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $48.97 · 2021: $62.56 · 2022: $252 · 2023: $671 · 2024: $749 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.74 |
| Education | $274.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $544.30 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Amgen INC. | $335.28 | 2020-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $247.47 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $240.42 | 2020-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $186.01 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $152.31 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $151.02 | 2024-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $146.84 | 2023-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $146.68 | 2023-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $138.69 | 2023-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $101.99 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $94.00 | 2023-2025 | Tarpeyo |
| Nxstage Medical, INC. | $72.44 | 2019 | |
| Novo Nordisk INC | $61.83 | 2023-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $53.93 | 2024-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $40.18 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ultragenyx Pharmaceutical INC. | $29.75 | 2023 | |
| Applied Medical Resources Corporation | $29.42 | 2022 | |
| Glaxosmithkline, LLC. | $26.42 | 2023 | Jesduvroq, Benlysta |
| Ardelyx, INC. | $22.35 | 2025 | Ibsrela |
| Vifor Pharma, INC. | $21.26 | 2025 | Veltassa |
| Boston Scientific Corporation | $16.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $14.52 | 2022 | |
| Horizon Therapeutics Plc | $13.25 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.